Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell Carcinoma

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2022-12-01

Last Posted Date: 2022-12-02

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT05633641

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Phase 2

Recruiting

Conditions: Nasopharyngeal Cancer

Interventions: Other: Induction chemotherapy and concurrent chemoradiation
Drug: Toripalimab

First Posted Date: 2022-11-29

Last Posted Date: 2022-11-29

Lead Sponsor: Fudan University

Target Recruit Count: 198

Registration Number: NCT05628922

Locations: 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China

The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer

Phase 2

Recruiting

Conditions: Recurrent Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: 5FU
Drug: folinic acid
Drug: Oxaliplatin
Drug: Irinotecan
Drug: Raltitrexed
Drug: Cetuximab
Drug: Bevacizumab
Radiation: Radiation

First Posted Date: 2022-11-28

Last Posted Date: 2024-10-01

Lead Sponsor: Fudan University

Target Recruit Count: 93

Registration Number: NCT05628038

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer

Recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Other: detect HPV and genetic variants

First Posted Date: 2022-11-02

Last Posted Date: 2022-11-02

Lead Sponsor: Fudan University

Target Recruit Count: 108

Registration Number: NCT05602831

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2022-10-26

Last Posted Date: 2023-04-04

Lead Sponsor: Fudan University

Target Recruit Count: 150

Registration Number: NCT05594082

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer
Advanced Breast Cancer
Breast Neoplasm
Breast Cancer
Hormone Receptor Positive Tumor

Interventions: Drug: PIK3CA inhibitor
Drug: AKT inhibitor
Drug: SHR-A1811
Drug: Carrelizumab
Drug: SHR-1167
Drug: Famitinib
Drug: Sorafenib
Drug: Everolimus
Drug: Fluzoparib
Drug: Aromatase Inhibitors or Fulvestrant
Drug: TPC
Drug: SHR-A1921
Drug: SHR-6209
Drug: Dalpiciclib
Drug: Apatinib
Drug: SHR-A2009
Drug: SHR-A2102
Drug: Goserelin
Drug: bevacizumab

First Posted Date: 2022-10-26

Last Posted Date: 2024-10-04

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT05594095

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma

Early Phase 1

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Behavioral: PK Blood Collection
Drug: CAR
Drug: TCR

First Posted Date: 2022-10-20

Last Posted Date: 2024-11-11

Lead Sponsor: Fudan University

Target Recruit Count: 24

Registration Number: NCT05587543

Locations: 🇨🇳
Fudan University, Shanghai, China

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Phase 2

Recruiting

Conditions: Breast Neoplasm
HER2-positive Breast Cancer
HER2-negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Breast Tumors
Hormone Receptor Negative Tumor
Triple-Negative Breast Cancer (TNBC)
Locally Advanced Breast Cancer
Early-stage Breast Cancer

Interventions: Drug: Nab paclitaxel
Drug: Camrelizumab
Drug: Pyrotinib
Drug: SHR-A1811
Drug: SHR-A1921
Drug: Pertuzumab
Drug: SHR-1316
Drug: Dalpiciclib
Drug: Trastuzumab
Drug: Goserelin
Drug: Carboplatin
Drug: Apatinib
Drug: Letrozole
Drug: Famitinib
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Fluzoparib

First Posted Date: 2022-10-17

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 716

Registration Number: NCT05582499

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Phase 2

Not yet recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab
Drug: pyrotinib
Drug: Dalpiciclib
Drug: fulvestrant

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 126

Registration Number: NCT05577923

Locations: 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

Novel Therapy Target in Metastatic Prostate Cancer

Not yet recruiting

Conditions: Prostate Neoplasms

Interventions: Other: Tissue

First Posted Date: 2022-10-13

Last Posted Date: 2022-10-13

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT05577689

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy